

GLAXOSMITHKLINE PLC  
Form 6-K  
February 18, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of a change in the interests of Dr M Slaoui, a Person Discharging Managerial Responsibility, in the American Depositary Shares (ADSs) of GlaxoSmithKline plc (the "Company") following transactions in the shares of a connected person, as follows:-

On 17 February 2009, Dr Slaoui's connected person, who is an employee of the Company, received the following awards:

| <b>Award under</b>                     | <b>ADSs</b> |
|--|-------------|
| GlaxoSmithKline Share Option Plan      | 5,940       |
| GlaxoSmithKline Share Value Plan       | 1,490       |
| GlaxoSmithKline Performance Share Plan | 2,620       |

The award of share options was made with an exercise price of US\$33.42 per ADS. The vesting date for all of these awards is 17 February 2012, subject, in the case of the Performance Share Plan award, to the Remuneration Committee having determined that the performance condition has been satisfied.

The Company and Dr Slaoui's connected person were advised of these transactions on 18 February 2009.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell  
Company Secretary

18 February 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 18 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc